
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Clinical PET Centre [C. J. H., O. S. H., A. A. L.] and Departments of Pulmonary Medicine [C. J. H., E. F. S.] and Clinical Epidemiology and Biostatistics [O. S. H.], VU University Medical Centre, 1007 MB Amsterdam, the Netherlands, and Departments of Nuclear Medicine [S. G. S.] and Pulmonary Medicine [J. F. V.], University Hospital Gasthuisberg, Leuven, Belgium
Purpose: As the interest in antiangiogenesis therapy in oncology is rising, the need for in vivo techniques to monitor such therapy is obvious. Measurement of tumor perfusion using positron emission tomography and H215O potentially is such a technique. The objective of the present study was to assess whether it is feasible to measure perfusion in vivo in non-small cell lung cancer (NSCLC) using H215O and positron emission tomography.
Experimental Design: Fifteen dynamic H215O and [18F]2-fluoro-2-deoxy-D-glucose (18FDG) studies were performed in 10 patients with stage IIIA-N2 NSCLC. Blood flow (BF) data were correlated with simplified methods of analysis (tumor:normal tissue ratio and standardized uptake value) and with glucose metabolism (MRglu).
Results: 18FDG data were required for accurate definition of tumor and mediastinal lymph node metastases. There was large intertumor variation in BF. Correlation of simplified methods of analysis with quantitative BF was poor. In addition, BF and MRglu were not correlated.
Conclusion: Measurement of BF in NSCLC using H215O and 18FDG is feasible. Simple uptake analysis, however, cannot be used as an indicator of perfusion. Whether BF can be used for response monitoring needs to be evaluated in a large patient study, where results can be compared with outcome.
This article has been cited by other articles:
![]() |
M. A. Lodge, H. A. Jacene, R. Pili, and R. L. Wahl Reproducibility of Tumor Blood Flow Quantification with 15O-Water PET J. Nucl. Med., October 1, 2008; 49(10): 1620 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. de Langen, V. E. M. van den Boogaart, J. T. Marcus, and M. Lubberink Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow Oncologist, June 1, 2008; 13(6): 631 - 644. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gupta, A. Saleem, B. Kotz, S. Osman, E. O. Aboagye, R. Phillips, C. Vernon, H. Wasan, T. Jones, P. J. Hoskin, et al. Carbogen and Nicotinamide Increase Blood Flow and 5-Fluorouracil Delivery but not 5-Fluorouracil Retention in Colorectal Cancer Metastases in Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3115 - 3123. [Abstract] [Full Text] [PDF] |
||||
![]() |
C M L West and N Charnley The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 50 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wells, T. Jones, and P. Price Assessment of Inter- and Intrapatient Variability in C15O2 Positron Emission Tomography Measurements of Blood Flow in Patients with Intra-abdominal Cancers Clin. Cancer Res., December 15, 2003; 9(17): 6350 - 6356. [Abstract] [Full Text] [PDF] |
||||
![]() |
G R Laking and P M Price Positron emission tomographic imaging of angiogenesis and vascular function Br. J. Radiol., December 1, 2003; 76(suppl_1): S50 - S59. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |